<DOC>
	<DOCNO>NCT00170053</DOCNO>
	<brief_summary>Kidney transplant patient treat Thymoglobulin ( 5 day ) , tacrolimus ( Prograf ) , mycophenolate mofetil ( Cellcept ) time transplant . They receive steroid 4 day prednisone . At 1 month , kidney biopsy ok , patient treat long term either continued tacrolimus/mycophenolate mofetil switch sirolimus ( Rapamune ) /mycophenolate mofetil . This do randomly manner similar flipping coin . The investigator try determine initial therapy patient stay steroid long term get good kidney function treat sirolimus compare tacrolimus . Patients follow 3 year repeat kidney biopsy 1 2 year transplant .</brief_summary>
	<brief_title>Comparison Sirolimus Tacrolimus Long Term Therapy Kidney Transplant With Steroids</brief_title>
	<detailed_description>Abstract : Corticosteroids mainstay immunosuppression kidney transplantation , associate significant toxicity long-term use . Recent study conclude steroid avoidance safe effective combine modern immunosuppressive maintenance therapy low risk kidney transplant recipient . These study include antilymphocyte induction therapy either anti IL-2 receptor antibody , antithymocyte globulin , rabbit polyclonal antithymocyte globulin ( Thymoglobulin ) . Mayo Clinic Scottsdale adopt Thymoglobulin induction , tacrolimus , mycophenolate mofetil rapid steroid taper standard immunosuppressive therapy low risk patient . Mayo Clinic Jacksonville also utilize protocol . Together , site utilize approach 64 patient . Recent improvement immunosuppressive regimen decrease acute rejection kidney transplant recipient increase one-year graft survival nearly 90 % . However , long-term graft survival change little 30 % graft lose `` chronic allograft nephropathy '' ( CAN ) first five year transplantation . A recent paper highlight dilemma demonstrated major cause late CAN chronic exposure nephrotoxic effect calcineurin inhibitor ( CNI ) tacrolimus cyclosporine possibly cytomegalovirus infection . In study , focus role CNI CAN . We propose prospective , randomize , non-blinded trial Thymoglobulin induction rapid steroid elimination accompany tacrolimus ( TAC ) mycophenolate mofetil ( MMF ) maintenance therapy . Patients randomize 1 month post-operatively either remain TAC/MMF switch SRL/MMF . The primary endpoint renal function 1-year post-transplant . Secondary endpoint include renal function 2 year post-transplant , histology see protocol biopsy 1 2 year post-transplant , incidence biopsy proven rejection 12 month , patient survival , graft survival , proportion patient steroid free 12 month , infectious complication , bone mineral density analysis , incidence hyperlipidemia , incidence new onset post-transplant diabetes mellitus .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>1 . Primary decease live donor renal transplant recipient 2 . Retransplant recipient first kidney transplant lose technical reason sensitization ( panelreactive antibody [ PRA ] &lt; 20 % ) 1st lose due recurrent disease , steroid responsive . 3 . Age &gt; 18 4 . Negative pregnancy test female childbearing age . In addition , female childbearing age must agree use effective contraception duration study . 5 . Patient must sign informed consent prior transplant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Kidney Transplantation</keyword>
</DOC>